Skip over main navigation
  • Log in
  • Basket: (0 items)
Duchenne UK
We fund more research than anyone else
    • Search for clinical trials
    • Donate
    • Twitter
    Menu
    • About Duchenne
      • What is Duchenne
      • Diagnosing Duchenne
      • Stages Of Duchenne
      • Current Treatments
      • Supporting Therapies
      • Treatments In The Pipeline
      • Understanding Clinical Trials
      • Clinical Trial Finder
    • Patient and Parent Support
      • What to do in an emergency
      • Coronavirus Resources
      • Our message for you
      • Caring for your child
      • Resources for parents
      • Free Information Days
      • Medical Care Guidelines
      • Decipha - education support
      • Patient and Parent Stories
      • Caring during the coronavirus pandemic
    • What We Do
      • Our Mission
      • Our Impact
      • Funding Research & Trials
      • Accelerating Drug Timeline
      • Community Engagement
      • DMD Care UK
      • DMD Hub
      • Project HERCULES
      • About Us
        • Meet The Team
        • President & Patrons
        • Scientific Advisory Board
        • Patient Advisory Board
        • Donor Advisory Board
        • Trustees
        • Joining Jack
        • Alex's Wish
        • Duchenne Now
      • Watch Our Film
      • Subscribe to our PODCAST
    • Support Us
      • Duchenne Dash
      • Fundraising Events
      • How You Can Help
      • Why Support Us?
      • Family and Friends Funds
      • Duchenne Direct
      • World's Strongest Boys
      • Corporate Support
    • News
    • Admin
      • Log in
    • Basket: (0 items)
    1. What We Do
    2. Funding Research & Trials

    Trials & Research We Fund

    Duchenne UK is a lean, ambitious and highly focused charity with a clear vision: to fund and accelerate treatments and a cure for Duchenne muscular dystrophy, to help this generation of patients with DMD.

    We believe strongly in partnerships, with academics and with biotechs. We fund all research, but we focus on translational projects, using our funds to help get promising therapies out of the laboratory and into the clinic where they can help patients. We believe in funding treatments that have a chance of making it to market, providing initial funding and then staying with them on that journey.

    To understand our impact and strategy please take a look at our infographic: download or open here. And read on for more detailed information about the individual projects we have funded.

    Apply for funding: If you would like to discuss an idea for a research project or make a proposal for us to consider funding, please contact us in the first instance by sending an e-mail to David Bull, Director of Research: [email protected].

    Please note that Duchenne UK does not pay indirect costs, or costs associated with normal overheads, as part of our funding awards for research projects.

    Duchenne UK is a member of AMRC.

    Read our animal research policy here. 

    Gene Therapy Overview

    Gene Therapy Overview

    An exciting new gene-based therapy on the horizon Read more

    Published: 1st October, 2015

    Updated: 9th February, 2021

    Author: Nick Crossley

    Comments: 1

    Repurposing Drugs

    Repurposing Drugs

    Already existing drugs developed for other conditions could be helpful to those with DMD Read more

    Published: 1st January, 2018

    Updated: 7th October, 2020

    Author: Nick Crossley

    Comments: 1

    Soy Products

    Soy Products

    Our new research project aims to discover if and why a fermented soy product called Haelan 951 may help those with DMD. Read more

    Published: 9th August, 2016

    Updated: 21st May, 2020

    Author: Nick Crossley

    Comments: 2

    Elastase inhibitors as a potential treatment for DMD

    Elastase inhibitors as a potential treatment for DMD

    Duchenne UK is co-funding a study into the use of elastase inhibitors to treat the symptoms of DMD in partnership with Joining Jack and Charley's Fund. Read more

    Published: 30th August, 2015

    Updated: 23rd January, 2019

    Author: Nick Crossley

    Solid Biosciences IGNITE DMD Clinical Trial

    Solid Biosciences IGNITE DMD Clinical Trial

    Solid Biosciences Gene Therapy Programme is currently in Phase I/II clinical trial for its investigational microdystrophin gene transfer for the treatment of Duchenne. Read more

    Published: 11th March, 2016

    Updated: 23rd January, 2019

    Author: Nick Crossley

    Statins - Simvastatin

    Statins - Simvastatin

    Duchenne UK partners with Solid Biosciences, to investigate the possible benefits of statins in patients. Can simvastatin reduce muscle damage and enhanced muscle function? Read more

    Published: 1st January, 2016

    Updated: 23rd January, 2019

    Author: Nick Crossley

    Vamorolone (VBP15) - Steroid Alternative

    Vamorolone (VBP15) - Steroid Alternative

    ReveraGen are running the clinical trial for Vamorolone which could offer a potential alternative to steroids Read more

    Published: 4th February, 2016

    Updated: 23rd January, 2019

    Author:

    Correction Of DMD Mutations Using Genome Surgery

    Correction Of DMD Mutations Using Genome Surgery

    Professor Dickson explores the technique of gene editing - cutting out the mutations that cause DMD Read more

    Published: 5th April, 2016

    Updated: 30th October, 2017

    Author: Nick Crossley

    Peptide Generation (PepGen) project

    Peptide Generation (PepGen) project

    Duchenne UK is pleased to announce its support of the development of the next generation of exon skipping drugs Read more

    Published: 1st August, 2015

    Updated: 24th October, 2017

    Author: Nick Crossley

    HT-100: A Drug To Treat Fibrosis And Inflammation

    HT-100: A Drug To Treat Fibrosis And Inflammation

    A clinical trial for an anti-inflammatory drug that could reduce the thickening of the muscles Read more

    Published: 11th March, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Summit Therapeutics Find New Biomarkers for DMD

    Summit Therapeutics Find New Biomarkers for DMD

    Summit Therapeutics found new biomarkers for DMD that could lead to new drugs related to SMT C1100 Read more

    Published: 4th April, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Developing New Chemical Compounds to Target DMD

    Developing New Chemical Compounds to Target DMD

    Discovering new follow-on compounds to increase utrophin levels more effectively than SMT C1100 Read more

    Published: 5th April, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Genome Editing To Repair DNA Duplications

    Genome Editing To Repair DNA Duplications

    Duplications in DNA can cause DMD. We are funding gene therapy research that aims to correct this. Read more

    Published: 5th April, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    The Biological Process Of Muscle Fibre Death

    The Biological Process Of Muscle Fibre Death

    The project investigates how muscle fibre cells die in DMD and looks at ways to prevent this Read more

    Published: 7th April, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Repairing The Stem Cells Of People With DMD

    Repairing The Stem Cells Of People With DMD

    Stem cell and gene therapy combine in this new study which aims to repair muscle cells and tissue Read more

    Published: 7th April, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Comments: 1

    Discovering Biomarkers For Duchenne Muscular Dystrophy

    Discovering Biomarkers For Duchenne Muscular Dystrophy

    Professor Wood of Oxford University examines muscle tissue MicroRNAs to see if they are valid biomarkers for DMD. Read more

    Published: 7th April, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Funding Canadian based genome-editing technology CRISPR

    Funding Canadian based genome-editing technology CRISPR

    We are supporting work on CRISPR, a gene correcting tool that is showing promise as a treatment for DMD Read more

    Published: 30th April, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Potential New Therapy to Treat Inflammation and Fibrosis

    Potential New Therapy to Treat Inflammation and Fibrosis

    We fund a programme investigating if an exisiting compound can benefit DMD Read more

    Published: 9th August, 2016

    Updated: 13th October, 2016

    Author: Nick Crossley

    Comments: 1

    Load more Back to top

    Showing 10 of 21

    DMD Hub

    DMD Hub

    Expanding Clinical trial capacity Read more

    Published: 1st March, 2015

    Updated: 26th June, 2019

    Author: Nick Crossley

    Attend our FREE Information Days

    Attend our FREE Information Days

    Please join us at our free Patient Information Day Read more

    Published: 27th July, 2017

    Updated: 13th October, 2020

    Author: Nick Crossley

    Comments: 1

    Impact Report 2020

    Impact Report 2020

    Despite the challenges of 2020, Duchenne UK has achieved much and we hope you find the impact report that we are releasing today, uplifting. Thank you for your support and we wish you a safe and bright 2021. Read more

    Published: 23rd December, 2020

    Updated: 27th January, 2021

    Author: Nick Crossley

    Latest tweet

    Sign up for our newsletter

    Please enter your first name
    Please enter your last name
    Please enter your email address Please enter a valid email address (e.g. [email protected])

    • Twitter
    • Facebook
    • Instagram
    • LinkedIn
    • Youtube

    Contact UsPrivacy Policy

    Registered Charity No. 1147094. © 2020 Duchenne UK. All rights reserved.
    A non profit company limited by guarantee. Registered in England No. 8030768

    Our mailing address is: Duchenne UK, Unit G20, Shepherd’s Building, Charecroft Way, Hammersmith, W14 0EE


    We will always store your personal details securely. We’ll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy or contact us on [email protected]